Bristol Myers Squibb Presents New 4-Year Sotyktu Data Demonstrate Durable Response Rates And Consistent Safety In Moderate-To-Severe Plaque Psoriasis
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (NYSE:BMY) announced new four-year results from the POETYK PSO long-term extension trial of Sotyktu (deucravacitinib) for moderate-to-severe plaque psoriasis. The data showed durable response rates and consistent safety, with no new safety signals observed.
May 16, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's new four-year data on Sotyktu demonstrates durable response rates and consistent safety in treating moderate-to-severe plaque psoriasis, with no new safety signals observed.
The positive long-term data on Sotyktu, showing durable response rates and consistent safety, is likely to boost investor confidence in Bristol Myers Squibb's product portfolio and future revenue potential. The absence of new safety signals further strengthens the drug's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100